Abstract
Fibromyalgia (FM) is a medically unexplained or functional somatic syndrome (FSS). The two classification criteria are chronic widespread pain (CWP) and the finding of 11/18 tender points (TP). FM overlaps and co-occurs with other FSSs, and auxiliary symptoms that are not included in the criteria may be clues to other FSSs. About ten FSSs include chronic fatigue syndrome, myofascial pain syndromes and irritable bowel syndrome. TP do not reflect demonstrable pathology, and are locations where everyone is generally more tender. In FM they are more tender than normal due to lowered pain threshold. High TP counts are associated with the extent of distress or unspecific somatic symptoms in the absence of chronic pain. TP lack validity and should be excluded. CWP and distress are outside the domain of rheumatology, and abnormal mechanisms in FM relate to the central nervous system, as compared to “peripheral” mechanisms studied in rheumatology. FM should not be considered as a rheumatologic condition but rather as part of a broader spectre of FSSs. Patients with FSSs should be considered and treated together across medical specialities by general physicians in primary health care.
Similar content being viewed by others
References
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160–172
Wolfe F (1996) The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol 23:534–539
Goldenberg DL (1999) Fibromyalgia syndrome a decade later: what have we learned? Arch Intern Med 159:777–785
Aaron LA, Buchwald D (2001) A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 134:868–881
Aaron LA, Buchwald D (2003) Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Baillieres Best Pract Res Clin Rheumatol 17:563–574
Wessely S, Nimnuan C, Sharpe M (1999) Functional somatic syndromes: one or many? Lancet 354:936–939
Nimnuan C, Rabe-Hesketh S, Wessely S, Hotopf M (2001) How many functional syndromes? J Psychosom Res 51:549–557
McBeth J, Macfarlane GJ, Hunt IM, Silman AJ (2001) Risk factors for persistent chronic widespread pain: a community-based study. Rheumatology 40:95–101
White KP, Nielson WR, Harth M, Ostbye T, Speechley M (2002) Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample. J Rheumatol 29:588–594
Gran JT (2003) The epidemiology of chronic generalized musculoskeletal pain. Baillieres Best Pract Res Clin Rheumatol 17:547–561
Henningsen P, Zimmermann T, Sattel H (2003) Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom Med 65:528–533
Croft P, Schollum J, Silman A (1994) Population study of tender point counts and pain as evidence of fibromyalgia. BMJ 309:696–699
Croft P, Burt J, Schollum J, Thomas E, Macfarlane G, Silman A (1996) More pain, more tender points: is fibromyalgia just one end of a continuous spectrum? Ann Rheum Dis 55:482–485
Simms RW (1998) Fibromyalgia is not a muscle disorder. Am J Med Sci 315:346–350
Le Goff P (2006) Is fibromyalgia a muscle disorder? Joint Bone Spine 73:239–242
Granges G, Littlejohn GO (1993) A comparative study of clinical signs in fibromyalgia/fibrositis syndrome, healthy and exercising subjects. J Rheumatol 20:344–351
Lautenbacher S, Rollman GB, McCain GA (1994) Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 59:45–53
Gracely RH, Grant MA, Giesecke T (2003) Evoked pain measures in fibromyalgia. Baillieres Best Pract Res Clin Rheumatol 17:593–609
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L (1995) The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19–28
Wolfe F, Ross K, Anderson J, Russell IJ (1995) Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 22:151–156
Pearce JM (2004) Myofascial pain, fibromyalgia or fibrositis? Eur Neurol 52:67–72
Wolfe F (2003) Stop using the American College of Rheumatology criteria in the clinic. J Rheumatol 30:1671–1672
Schochat T, Raspe H (2003) Elements of fibromyalgia in an open population. Rheumatology 42:829–835
Wolfe F, Skevington SM (2000) Measuring the epidemiology of distress: the rheumatology distress index. J Rheumatol 27:2000–2009
Wolfe F (1997) The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Ann Rheum Dis 56:268–271
Guidelines for the development of practice guidelines. American College of Rheumatology (1998). Available through http://www.rheumatology.org
Clauw DJ, Crofford LJ (2003) Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Baillieres Best Pract Res Clin Rheumatol 17:685–701
Katz RS, Wolfe F, Michaud K (2006) Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum 54:169–176
Burckhardt CS, Clark SR, Bennett RM (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733
Wolfe F, Hawley DJ, Goldenberg DL, Russel IJ, Buskila D, Neumann L (2000) The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol 27:1989–1999
Clauw DJ (1995) The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med Hypotheses 44:369–378
Evengard B, Klimas N (2002) Chronic fatigue syndrome: probable pathogenesis and possible treatments. Drugs 62:2433–2446
Cho HJ, Skowera A, Cleare A, Wessely S (2006) Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. Curr Opin Psychiatry 19:67–73
Farber L, Haus U, Spath M, Drechsler S (2004) Physiology and pathophysiology of the 5-HT3 receptor. Scand J Rheumatol Suppl 119:2–8
Geracioti TD Jr, Carpenter LL, Owens MJ, Baker DG, Ekhator NN, Horn PS, Strawn JR, Sanacora G, Kinkead B, Price LH, Nemeroff CB (2006) Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163:637–643
Owens MJ, Nemeroff CB (1994) Role of serotoin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40:288–295
Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrrou M, Alvado G, Gomeni C (2001) Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology 40:290–296
Axelson DA, Perel JM, Birmaher B, Rudolph G, Nuss S, Yurasits L, Bridge J, Brent DA (2005) Platelet serotonin reuptake inhibition and response to SSRIs in depressed adolescents. Am J Psychiatry 162:802–804
Goldenberg DL, Burckhardt C, Crofford L (2004) Management of fibromyalgia syndrome. JAMA 292:2388–2395
Evengard B, Nilsson CG, Lindh G, Lindquist L, Eneroth P, Fredrikson S, Terenius L, Henriksson KG (1998) Chronic fatigue syndrome differs from fibromyalgia: no evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 78:153–155
Lindh C, Liu Z, Lyrenas S, Ordeberg G, Nyberg F (1997) Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc. Scand J Rheumatol 26:468–472
De Stefano R, Selvi E, Villanova M, Frati E, Manganelli S, Franceschini E, Biasi G, Marcolongo R (2000) Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 27:2906–2910
Goldberg J, Davidson P (1997) A biopsychosocial understanding of the irritable bowel syndrome: a review. Can J Psychiatry 42:835–840
Tsigos C, Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53:865–871
Riedel W, Schlapp U, Leck S, Netter P, Neeck G (2002) Blunted ACTH and cortisol responses to systemic injection of corticotropin-releasing hormone (CRH) in fibromyalgia: role of somatostatin and CRH-binding protein. Ann NY Acad Sci 966:483–490
Cleare AJ (2003) The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 24:236–252
Mayer EA, Craske M, Naliboff BD (2001) Depression, anxiety, and the gastrointestinal system. J Clin Psychiatry 62(Suppl 8):28–36
Mease PJ, Clauw DJ, Arnold LM, Goldenberg DL, Witter J, Williams DA, Simon LS, Strand CV, Bramson C, Martin S, Wright TM, Littman B, Wernicke JF, Gendreau RM, Crofford LJ (2005) Fibromyalgia syndrome. J Rheumatol 32:2270–2277
Kroenke K, Spitzer RL, deGruy FV III, Swindle R (1998) A symptom checklist to screen for somatoform disorders in primary care. Psychosomatics 39:263–272
Aggarwal VR, McBeth J, Zakrzewska JM, Lunt M, Macfarlane GJ (2006) The epidemiology of chronic syndromes that are frequently unexplained: do they have common associated factors? Int J Epidemiol 35:468–476
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Endresen, G.K.M. Fibromyalgia: a rheumatologic diagnosis?. Rheumatol Int 27, 999–1004 (2007). https://doi.org/10.1007/s00296-007-0402-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-007-0402-x